Clinical Trials ArenaOriginal article
AstraZeneca pins bone disease drug’s Phase III failure on high placebo response
Phase 3negativeefzimfotase alfaNegative
AI Analysis
Summary
AstraZeneca's Phase III trial of efzimfotase alfa for hypophosphatasia missed its primary endpoint, with the company attributing the failure to a high placebo response. Despite the setback, AstraZeneca intends to pursue bringing the drug to patients.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Not Met
Outcome Details
Primary endpoint miss; attributed to high placebo response
Importance:7/10
Sentiment:
-0.70
phase_3_failurebone_diseasehypophosphatasiaplacebo_response
Related Companies
Read the original article
Published by Clinical Trials Arena on October 12, 2026 10:42 AM